How to Cite
Abstract
Beta-thalassemia is a congenital disorder generally caused by point mutations in the gene that encodes for the synthesis of globin beta chains, which produces an ineffective erythropoiesis phenomenon, and reduces the half-life of erythrocytes in the most severe forms. However, the classification includes forms of thalassemia of various clinical behaviors; from severe forms to asymptomatic forms. Complications are usually associated with the chronic treatment utilized in this disorder, which includes repeated blood transfusions, amongst others. New therapies seek to reduce the adverse effects associated with transfusions, as well as targeting genetic components of the disease.
Keywords
References
Origa R. β-Thalassemia.Genetics in Medicine [Internet]. 2016 [Citado 27/06/2020];19(6):609-619. https://doi.org/10.1038/gim.2016.173
Shah F, Sayani F, Trompeter S, Drasar E, Piga A. Challenges of blood transfusions in β-thalassemia, Blood Reviews [Internet]. 2019 [Citado 27/06/2020]; 37:100588. https://doi.org/10.1097/gim.0b013e3181cd68ed.
Cappellini M, Porter J, Viprakasit V, Taher A. A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies? Blood Reviews [Internet]. 2018 [Citado 27/06/2020];32(4):300-311. https://doi.org/10.1016/j.bj.2015.10.001
Taher A, Karakas Z, Cassinerio E, Siritanaratkul N, Kattamis A, Maggio A et al. Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study. Blood [Internet]. 2018 [Citado 29/06/2020];131(2):263-265.https://doi.org/10.1182/blood-2017-06-790121
Hoffman R, Benz E, Silberstein L, Heslop H, Weitz J, Anastasi J et al. Hematology. Philadelphia, PA: Elsevier; 2018.
Khandros E, Kwiatkowski J. Beta Thalassemia. Hematology/Oncology Clinics of North America [Internet] 2019 [Citado 28/06/2020];33(3):339-353.https://doi.org/10.1016/j.hoc.2019.01.003
de Dreuzy E, Bhukhai K, Leboulch P, Payen E. Current and future alternative therapies for beta-thalassemia major. Biomedical Journal [Internet]. 2016 [Citado 25/06/2020];39(1):24-38. https://dx.doi.org/10.1016%2Fj.bj.2015.10.001
Salah, Naouel Ben, et al. Revisiting Beta Thalassemia Intermedia: Past, Present, and Future Prospects. Hematology [Internet]. 2017 [Citado 1/08/2020];22(20):607-616. https://doi.org/10.1080/10245332.2017.1333246
Hoffbrand A, Steensma, P. Essential Hematology. Philadelpia, PA: Wiley Blackwell, 2019.
Cappellini M, Viprakasit V, Taher A, Georgiev P, Kuo K, Coates T et al. A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia. New England Journal of Medicine. [Internet] 2020 [Citado 29/06/2020] ;382(13):1219-1231. https://doi.org/10.1056/nejmoa1910182
Betts, Marissa, et al. Systematic Literature Review of the Burden of Disease and Treatment for Transfusion-Dependent β-Thalassemia. Clinical Therapeutics [Internet]. 2020 [Citado 29/06/2020]; 42(2):322-337.https://doi.org/10.1016/j.clinthera.2019.12.003
Soni S. Novel and innovative approaches for treatment of β-thalassemia. Pediatric Hematology Oncology Journal [Internet]. 2017 [Citado 29/06/2020];2(4):121-126.https://doi.org/10.1016/j.phoj.2017.11.153
El-Beshlawy, Amal, and Mona El-Ghamrawy. Recent Trends in Treatment of Thalassemia. Blood Cells, Molecules, and Diseases [Internet]. 2019 [Citado 29/06/2020]; 79:53-59. https://doi.org/10.1016/j.bcmd.2019.01.006
Thein S. Molecular basis of β thalassemia and potential therapeutic targets. Blood Cells, Molecules, and Diseases [Internet]. 2018 [Citado 29/06/2020]; 70:54-65.https://dx.doi.org/10.1016%2Fj.bcmd.2017.06.001
Richard F, Lier J, Roubert B, Haboubi T, Göhring U, Dürrenberger F. Oral ferroportin inhibitor VIT‐2763: First‐in‐human, phase 1 study in healthy volunteers. American Journal of Hematology [Internet]. 2019 [Citado 29/06/2020];95(1):68-77.https://dx.doi.org/10.1002%2Fajh.25670
Karponi G, Zogas N. Gene Therapy for Beta-Thalassemia: Updated Perspectives. The Application of Clinical Genetics [Internet]. 2019 [Citado 29/06/2020]; 12:167-180. https://dx.doi.org/10.2147%2FTACG.S178546
Boulad, Farid, et al. Gene Therapy and Genome Editing.” Hematology/Oncology Clinics of North America [Internet]. 2018 [Citado 29/06/2020]; 32(2):329-342. https://doi.org/10.1016/j.hoc.2017.11.
Wienert, Beeke, et al. Wake-up Sleepy Gene: Reactivating Fetal Globin for β-Hemoglobinopathies. Trends in Genetics [Internet]. 2018 [Citado 29/06/2020]; 34(12): 927-940. https://doi.org/10.1016/j.tig.2018.09.004
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2020 Array